In brief, intricate interactions exist between epigenetic alterations and NRF2/KEAP1 signaling, thus selective epigenetic therapeutics targeting NRF2/KEAP1 signaling based on a deeper understanding of contextual and temporal control of NRF2-mediated effects will benefit the development of novel tumor treatments. The gene discussed is NFE2L2; the disease is neoplasm.